CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced its intention to publicly offer
$80 million principal amount of senior convertible notes due 2011. The
company would grant to the underwriters an overallotment option to purchase an
additional $12 million principal amount of the notes within 30 days after the
offering. JP Morgan Securities Inc. will be the sole book-running manager for
the offering, SG Cowen & Co., LLC will be the joint lead manager for the
offering and Pacific Growth Equities, LLC and RBC Capital Markets will be co-
managers.
A shelf registration statement relating to the notes that the company
intends to sell has previously been filed with, and declared effective by, the
Securities and Exchange Commission. Any offer, if at all, will be made only
by means of a prospectus and a prospectus supplement. A copy of the
prospectus and prospectus supplement related to the offering can be obtained
when available from the Prospectus Department of JP Morgan Securities Inc.,
One Chase Manhattan Plaza, Floor 5b, New York, NY 10081.
The securities may not be sold nor may offers to buy be accepted prior to
the time that the prospectus supplement is final. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and Latin America.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.
CONTACTS:
Justine E. Koenigsberg
Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Director, Corporate
Communications, +1- 617-349-0271, or Daniella M. Lutz, Corporate
Communications Specialist, +1- 617-349-0205, both of TKT
|
